(Q34621447)

3 August 2017

1 reference

title

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence (English)

1 reference

Lolkje T W de Jong-van den Berg

3 August 2017

author

6

object named as

Lolkje T W de Jong-van den Berg

1 reference

3 August 2017

1

Maarten J Postma

1 reference

3 August 2017

Paul Jansema

2

1 reference

3 August 2017

Marianne L L van Genugten

3

1 reference

3 August 2017

Marie-Louise A Heijnen

4

1 reference

3 August 2017

Johannes C Jager

5

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

62

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

1013-1024

1 reference

Cost-effectiveness league tables: More harm than good?

3 August 2017

cites work

1 reference

12 December 2020

The socioeconomics of influenza and its control measures. Proceedings of a symposium. Geneva, Switzerland, 5-6 October 1998

1 reference

12 December 2020

The swine-influenza decision

1 reference

12 December 2020

Review of cost-benefit analyses of influenza vaccine

1 reference

12 December 2020

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population

1 reference

12 December 2020

Influenza vaccination

1 reference

12 December 2020

An exercise on the feasibility of carrying out secondary economic analyses

1 reference

12 December 2020

Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company

1 reference

12 December 2020

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

1 reference

12 December 2020

Effectiveness of influenza vaccine in health care professionals: a randomized trial

1 reference

12 December 2020

Emerging infections: pandemic influenza

1 reference

12 December 2020

Vaccination against influenza: a five-year study in the Post Office

1 reference

12 December 2020

A perspective on the significance of pandemic influenza

1 reference

12 December 2020

Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

1 reference

12 December 2020

Influenza vaccine for healthy working adults

1 reference

12 December 2020

Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines

1 reference

12 December 2020

Influenza vaccine for healthy working adults

1 reference

12 December 2020

Influenza vaccine for healthy adults?

1 reference

12 December 2020

The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals

1 reference

12 December 2020

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

1 reference

12 December 2020

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.

1 reference

12 December 2020

The effectiveness of vaccination against influenza in healthy, working adults.

1 reference

12 December 2020

Preventing influenza in healthy adults: the evolving story

1 reference

12 December 2020

Estimates of the US health impact of influenza

1 reference

12 December 2020

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention

1 reference

12 December 2020

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence

1 reference

12 December 2020

Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Interpretation of cost-effectiveness analyses

1 reference

12 December 2020

Influenza vaccination among healthy employees: a cost-benefit analysis

1 reference

12 December 2020

Antigenic drift and efficacy of influenza virus vaccines, 1976--1977

1 reference

12 December 2020

French economic evaluations of influenza and influenza vaccination

1 reference

12 December 2020

Prevention and early treatment of influenza in healthy adults

1 reference

12 December 2020

Lowering the age for influenza vaccination

1 reference

12 December 2020

Anti-influenza vaccination for active persons (25-64 years): a cost-benefit study

1 reference

12 December 2020

Sickness absence following a campaign of vaccination against influenza in the workplace

1 reference

12 December 2020

Economic impact of influenza. The individual's perspective

1 reference

12 December 2020

Effectiveness and cost-benefit of an influenza vaccination program for health care workers

1 reference

12 December 2020

Swine influenza vaccine and Guillain-Barré syndrome. Epidemic or artifact?

1 reference

12 December 2020

Cost-effectiveness of the influenza vaccine in a healthy, working-age population.

1 reference

12 December 2020

10.2165/00003495-200262070-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1012571404

0 references

1 reference